Cell One Partners and Center for Breakthrough Medicines Announce Strategic Partnership to Accelerate Cell and Gene Therapy Commercialization
Cell One Partners, an industry-leading strategic consulting firm positioned to support cell and gene therapy (CGT) companies with scientific and commercial expertise to guide their research from laboratory to commercialization, and King of Prussia-based Center for Breakthrough Medicines (CBM), a cell and gene therapy contract development and manufacturing organization (CDMO), has announced a strategic partnership to accelerate the development and commercialization of cell and gene therapies.
Cell One Partners provides its clients with virtual company creation and management for all aspects of drug development and commercialization. This partnership combines Cell One Partners’ strategic vision of enabling new company formation through virtual executive leadership and program management to accelerate assets from the bench to the clinic and finally to market with CBM’s commitment to providing industry-leading technologies, capabilities, and massive capacity for end-to-end development, testing, and manufacturing of lifesaving therapies.
“Our unique model of creating and managing virtual companies for CGT asset owners allows them to accelerate their pathway to commercialization via our unparalleled network of cell and gene therapy leaders and innovators to support all aspects of the development, manufacturing, and commercialization continuum at about one-third of the management cost of setting up a traditional company with C-level executives,” said George S. Goldberger, Founder and Chief Executive Officer of Cell One Partners. “The Center for Breakthrough Medicines is a valuable asset to our clients as their integrated, end-to-end services, all located in a single complex, allow innovator companies to optimize their working capital and focus on driving the science toward commercialization.”
A barrier for many early-stage CGT development companies, including those tied to academic institutions, is a lack of access to senior C-suite leadership who can provide counsel and guidance on all aspects of getting a therapy from idea to clinic, including clinical development planning, product pipeline assessment, management and organizational development, and regulatory and approval pathway development. Cell One Partners’ unique, virtual company creation removes those barriers by providing virtual, world-class management at typically one-third of the cost of a traditional new company start-up, allowing the asset owner to focus both their cash and energies on research and development.
Through this strategic partnership with CBM, on track to be the world’s largest single CGT manufacturing site with more than 700,000 sq. ft. of manufacturing and testing facilities, including 30-plus GMP suites, CGT asset owners will have unparalleled access to end-to-end services to support research and development, process development, and clinical and commercial manufacturing, including starting materials (plasmid and nucleic acid synthesis) and cell banking. Cell One Partners believes a partnership with CBM positions its clients for success via an innovative virtual company creation, management strategy, and structure while delivering a cost-effective, future-oriented model for cell and gene therapy development, manufacturing, and commercialization.
“The missions of our two organizations are aligned – to advance cell and gene therapy research from idealization to commercialization in an effort to save lives,” said Jennifer Manning, SVP of Global Strategic Partnerships at CBM. “A strategic partnership with Cell One Partners provides CGT developers access to Cell One Partners’ virtual C-Suite executives and strategic advisors and access to CBM’s expansive capacity, breadth of CGT technologies, R&D, process development and GMP manufacturing expertise, allowing innovators to focus on research, extend cash runway, simplify a complex supply chain, and accelerate the development and manufacturing of their therapies.”
- NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
- Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
- Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
- Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more
- Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) Read more